tapentadol phosphate: clinical use

Prescribing considerations

• Reserve the selected prolonged-release products for severe chronic pain in adults requiring opioid analgesia; they are not licensed for acute pain.
• Agree meaningful treatment goals, review continued benefit and harms, and establish a discontinuation plan before treatment.
• Assess respiratory disease, sleep-disordered breathing, hepatic and renal function, seizure risk, mental health, substance-use history and concurrent sedating medicines.
• Avoid use for acute postoperative pain because of ventilatory impairment and persistent opioid-use risks.
• Switching between opioids or formulations requires individual clinical assessment; do not assume simple equivalence.

Contraindications and cautions

• Hypersensitivity to tapentadol or product excipients
• Significant respiratory depression in an unmonitored setting
• Acute or severe bronchial asthma or hypercapnia
• Known or suspected paralytic ileus
• Acute intoxication with alcohol, hypnotics, centrally acting analgesics or psychotropic substances

Monitoring

• Pain, function and progress toward agreed treatment goals
• Sedation, respiratory rate and signs of opioid-induced ventilatory impairment
• Constipation, nausea and other treatment-limiting adverse effects
• Tolerance, withdrawal, early refill requests, loss of control or other signs of opioid use disorder
• New seizures, serotonergic toxicity or altered mental state where interacting medicines are present
• Renal and hepatic status where impairment is known or suspected
• New sleep apnoea symptoms or sleep-related hypoxaemia

Clinical pharmacology

Tapentadol combines mu-opioid receptor agonism with noradrenaline reuptake inhibition. It is extensively metabolised, predominantly by glucuronidation; its metabolites are not analgesically active, and cytochrome P450 metabolism is a minor pathway.

Formulation and product differences

• The selected tablet is a prolonged-release matrix tablet that must be swallowed whole; its empty matrix may occasionally be visible in stools after the active ingredient has been absorbed.
• The selected hard capsule contains prolonged-release pellets. It may be swallowed whole or opened and sprinkled onto cold soft food, but neither the capsule contents nor pellets may be crushed or chewed.
• The selected prolonged-release capsule is reported as bioequivalent to prolonged-release tablets, but administration instructions remain product-specific.

Modified-release capsule

Route: Oral

Strengths: 50 mg, 100 mg, 150 mg, 200 mg, 250 mg